Health News Releases

  • Today September 26
September 05, 16:45
CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 20
September 02, 16:55
U.S. FDA approves first treatment option for generalized pustular psoriasis flares in adults
The U.S. Food and Drug Administration is the first regulatory authority to approve spesolimab as a treatment option for generalized pustular psoriasis (GPP) flares in adults, Boehringer Ingelheim anno
September 02, 15:30
Biocytogen Lists on the Main Board of HKEX, Aiming to Become the Headstream of New Drugs
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced the company’s official listing on the Main Board of the Stock Exchange of Hong Kong. Government representatives, sh
September 01, 17:10
Aster Guardians Global Nursing Award 2023 Worth US $250,000 is Now Open for Nominations from Nurses Worldwide
In its continued efforts to recognize the contribution of nurses to mankind and to the healthcare community, Aster DM Healthcare has announced the next edition of the Aster Guardians Global Nursing Aw
HK inno.N CI
September 01, 14:19
GICELL to Collaborate with HK inno.N on Research and Development for next-generation CAR-NK Therapy
GICELL announced research and development collaboration for allogeneic CAR-NK candidates with HK inno.N on August 29th, 2022. The companies plan to advance the development of numerous CAR-NK therap
August 31, 09:00
US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the
August 30, 18:00
Aleph Farms Joins AIM for Climate as Newest Innovation Sprint Partner to Advance Cellular Agriculture
Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced that it has been officially recognized by the Agriculture Innovatio
August 29, 14:45
Covetrus Names Margie B. Pritchard General Counsel
Covetrus® (NASDAQ: CVET), a global leader in animal-health technology and services, today announced the appointment of Margie B. Pritchard as General Counsel and Corporate Secretary, reporting to Ben
August 29, 13:30
The Polypill Reduces Cardiovascular Mortality by 33% in Patients Treated After Myocardial Infarction
The polypill developed by the CNIC and Ferrer, which includes three drugs (aspirin, an angiotensin-converting enzyme (ACE) inhibitor, and a statin), is effective at preventing secondary adverse cardio
August 26, 14:00
PCI Pharma Services Opens New England Center of Excellence to Bring Global Clinical Supply Capabilities to New England
PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced the opening of its Clinical Services Center of Excellence in Bridgewater, MA, th
August 25, 15:40
Galderma Delivers Strong H1 2022 Results and Continued Innovation Across Its Leading Dermatology Portfolio
Galderma: Continued strong commercial and financial performance in a resilient market · Galderma delivered continued strong growth across product categories, with net sales up 15% year-on-year o
August 25, 13:30
Biocytogen Expands Partnership with Merck
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered into a global licensing agreement with Merck for the use of Biocytogen’s RenMice™ platform. Under the terms of the agreement, Merc
August 25, 10:30
AdvanCell Closes A$18M Series B Funding Led by Morningside
AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Serie
August 24, 16:20
Morinaga Milk Obtains FDA GRAS Notification for its Probiotic
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium longum subsp. infantis M-63 has received FDA GRAS (Ge
August 24, 14:40
Frazier Life Sciences Adds Senior R&D Leader to Team
Frazier Life Sciences announced the addition of Annette Doherty, Ph.D., OBE, FRSC as a Senior Advisor. She has 35 years of international experience as a chemist and leader of pharmaceutical research a
Miracor Medical Announces FDA IDE Approval For PiCSO® Pivotal Study
August 23, 17:00
Miracor Medical Announces FDA IDE Approval For PiCSO® Pivotal Study
Miracor Medical SA (Miracor Medical) has announced the approval of an Investigational Device Exemption (IDE) from the FDA, enabling the company to initiate a pivotal study with its Pressure-controlled
August 23, 16:50
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment
August 23, 16:20
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
Takeda (TSE:4502/NYSE:TAK) today announced the company’s dengue vaccine, QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003), was approved by the Indonesia National Agency for Drug and F
August 23, 14:00
Medisca Unveils New Brand Identity and Corporate Positioning as Partners in Wellness
After three successful decades of redefining, shaping, and informing the pharmaceutical compounding industry standard, Medisca is proud to unveil a new global brand identity and corporate positioning
August 23, 11:35
Solasia Announces Launch of Darvias® in Japan
Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (S
August 22, 16:30
VFMCRP announces U.S. Court upholds validity of Velphoro® patent
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s favor regarding U.S. patent no. 9,561,251 whi
August 19, 14:50
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Produ
August 18, 16:40
Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England’s National Institute for Health and Care Excellence (NICE) has recommended Tavneos® in combination with a rituxim
August 10, 11:10
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) will hold a meeting on September 22
August 05, 11:10
GenomOncology and Congenica Announce Collaborative Development of Novel Precision Oncology Solution
Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a nov
25 per page50 per page75 per page100 per page